Evidence map›Paper›PMID 26077675›Full record

ArticleJournal of translational medicine2015

Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.

Michal Ganz, Terence N Bukong, Timea Csak, Banishree Saha, Jin-Kyu Park, Aditya Ambade, Karen Kodys, Gyongyi Szabo

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Oligonucleotide therapies for nonalcoholic steatohepatitis.Molecular therapy. Nucleic acids · 2024
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. A missense variant in human perilipin 2 (JHEP reports : innovation in hepatology · 2024
    Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Michal GanzDepartment of Medicine, University of Massachusetts Medical School, 364 Plantation St, LRB-208, Worcester, MA, 01605, USA. mganz1@gmail.com.
Terence N BukongDepartment of Medicine, University of Massachusetts Medical School, 364 Plantation St, LRB-208, Worcester, MA, 01605, USA. terence.bukong@umassmed.edu.
Timea CsakDepartment of Medicine, University of Massachusetts Medical School, 364 Plantation St, LRB-208, Worcester, MA, 01605, USA. timea.csak@umassmed.edu.
Banishree SahaDepartment of Medicine, University of Massachusetts Medical School, 364 Plantation St, LRB-208, Worcester, MA, 01605, USA. banishree.saha@umassmed.edu.
Jin-Kyu ParkDepartment of Medicine, University of Massachusetts Medical School, 364 Plantation St, LRB-208, Worcester, MA, 01605, USA. jin-kyu.park@yale.edu.
Aditya AmbadeDepartment of Medicine, University of Massachusetts Medical School, 364 Plantation St, LRB-208, Worcester, MA, 01605, USA. aditya.ambade@umassmed.edu.
Karen KodysDepartment of Medicine, University of Massachusetts Medical School, 364 Plantation St, LRB-208, Worcester, MA, 01605, USA. karen.kodys@umassmed.edu.
Gyongyi SzaboDepartment of Medicine, University of Massachusetts Medical School, 364 Plantation St, LRB-208, Worcester, MA, 01605, USA. gyongyi.szabo@umassmed.edu.
University of Massachusetts Chan Medical School · US

Funding

TLR4 Signaling in alcoholic liver diseaseR01AA017729 · NIAAA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SZABO, GYONGYI · 2009 to 2021
$4.3M
NIAAA NIH HHS AA017729NIAAA NIH HHS R01 AA017729
6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD) is becoming a pandemic. While multiple 'hits' have been reported to contribute to NAFLD progression to non-alcoholic steatohepatitis (NASH), fibrosis and liver cancer, understanding the natural history of the specific molecular signals leading to hepatocyte damage, inflammation and fibrosis, is hampered by the lack of suitable animal models that reproduce disease progression in humans. The purpose of this study was first, to develop a mouse model that closely mimics progressive NAFLD covering the spectrum of immune, metabolic and histopathologic abnormalities present in human disease; and second, to characterize the temporal relationship between sterile/exogenous danger signals, inflammation, inflammasome activation and NAFLD progression.

methodsMale C57Bl/6 mice were fed a high fat diet with high cholesterol and a high sugar supplement (HF-HC-HSD) for 8, 27, and 49 weeks and the extent of steatosis, liver inflammation, fibrosis and tumor development were evaluated at each time point.

resultsThe HF-HC-HSD resulted in liver steatosis at 8 weeks, progressing to steatohepatitis and early fibrosis at 27 weeks, and steatohepatitis, fibrosis, and tumor development at 49 weeks compared to chow diet. Steatohepatitis was characterized by increased levels of MCP-1, TNFα, IL-1β and increased liver NASH histological score. We found increased serum levels of sterile danger signals, uric acid and HMGB1, as early as 8 weeks, while endotoxin and ATP levels increased only after 49 weeks. Increased levels of these sterile and microbial danger signals paralleled upregulation and activation of the multiprotein complex inflammasome. At 27, 49 weeks of HF-HC-HSD, activation of M1 macrophages and loss of M2 macrophages as well as liver fibrosis were present. Finally, similar to human NASH, liver tumors occurred in 41% of mice in the absence of cirrhosis and livers expressed increased p53 and detectable AFP.

conclusionsHF-HC-HSD over 49 weeks induces the full spectrum of liver pathophysiologic changes that characterizes the progression of NAFLD in humans. NAFLD progression to NASH, fibrosis and liver tumor follows progressive accumulation of sterile and microbial danger signals, inflammasome activation, altered M1/M2 cell ratios that likely contribute to NASH progression and hepatic tumor formation.

Indexed as

Disease ProgressionAnimalsBiomarkersBody WeightCholesterolCytokinesDietary CarbohydratesDiet, High-FatDisease Models, AnimalFeeding BehaviorFemaleInflammasomesInflammationInflammation MediatorsInsulinKupffer CellsBiomarkersCholesterolCytokinesDietary CarbohydratesInflammasomesInflammation MediatorsInsulin

Identifiers

PMID26077675
PMCPMC4467677
OpenAlexW2101286220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.